JAKs and STATs in Immunity, Immunodeficiency, and Cancer
Top Cited Papers
- 10 January 2013
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (2), 161-170
- https://doi.org/10.1056/nejmra1202117
Abstract
A large number of cytokines signal through the JAK–STAT pathway. Abnormal function of this pathway may lead to a variety of diseases. Targeting the defects in this signaling pathway has already led to treatment advances, and further advances are likely.Keywords
This publication has 101 references indexed in Scilit:
- A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE SyndromeThe Journal of Pediatrics, 2012
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- A genome-wide association study of plasma total IgE concentrations in the Framingham Heart StudyJournal of Allergy and Clinical Immunology, 2012
- Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitisNature Genetics, 2011
- A Critical Role for STAT3 Transcription Factor Signaling in the Development and Maintenance of Human T Cell MemoryImmunity, 2011
- NF-κB and STAT3 – key players in liver inflammation and cancerCell Research, 2010
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survivalLeukemia, 2010
- Cooperative Epigenetic Modulation by Cancer Amplicon GenesCancer Cell, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005